trending Market Intelligence /marketintelligence/en/news-insights/trending/HpmPEUfCe0LjnaD8cfvGdg2 content esgSubNav
In This List

Jazz Pharmaceuticals receives US FDA priority review for leukemia drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Jazz Pharmaceuticals receives US FDA priority review for leukemia drug

The U.S. Food and Drug Administration granted priority review status to the new drug application for Jazz Pharmaceuticals plc's Vyxeos liposome injection, an investigational drug for acute myeloid leukemia, a rapidly progressing and life-threatening blood cancer.

Jazz Pharmaceuticals' application contains clinical data from five studies, including a phase 3 trial which met its primary endpoint.

The drug was previously granted breakthrough therapy designation by the FDA in May 2016 to treat adult patients with therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. It also received fast track designation from the FDA to treat elderly patients with secondary acute myeloid leukemia.

Vyxeos has also received orphan drug designation from the FDA and European Commission for the treatment of acute myeloid leukemia.